MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms : three-year follow-up of the austrian stroke prevention study.

White matter lesions (WMLs) on magnetic resonance imaging (MRI) scans of older persons are thought to be caused by cerebral small-vessel disease. As they progress, these brain abnormalities frequently result in cognitive decline and gait disturbances, and their predictors are incompletely understood. Genetic risk factors have been implicated but remain undetermined so far. We examined whether 2 common polymorphisms of the paraoxonase (PON1) gene leading to a methionine (M allele)-leucine (L allele) interchange at position 54 and an arginine (B allele)-glutamine (A allele) interchange at position 191 are associated with the presence and progression of WMLs. We studied 264 community-dwelling subjects without neuropsychiatric disease (ages 44 to 75 years). All underwent vascular risk factor assessment, brain MRI, and PON1 genotyping. MRI scanning was repeated after 3 years. The extent and number of WMLs were recorded by 3 independent readers. Progression of WMLs was assessed by direct scan comparison. The final rating relied on the majority judgment of the 3 readers. The LL, LM, and MM genotypes were noted in 111 (42.0%), 118 (44.7%), and 35 (13.3%) subjects, respectively; the AA, AB, and BB genotypes occurred in 146 (55.3%), 98 (37.1%), and 20 (7.8%) individuals, respectively. Carriers of the LL genotype showed a nonsignificant trend toward more extensive WMLs and more frequently demonstrated lesion progression over the 3-year observation period (P=0.03). The polymorphism at position 191 had no effect. Logistic regression analysis yielded age (odds ratio, 1.08/y), diastolic blood pressure (odds ratio, 1.05/mm Hg), and LL paraoxonase genotype (odds ratio, 2. 65) to be significant predictors of WML progression. These data suggest that the LL PON1 genotype at position 54 influences the extent and progression of WMLs in elderly subjects.

[1]  T. Manolio,et al.  Relationships of cerebral MRI findings to ultrasonographic carotid atherosclerosis in older adults : the Cardiovascular Health Study. CHS Collaborative Research Group. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[2]  R. Schmidt,et al.  Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. , 1998, Stroke.

[3]  J. Miller,et al.  Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. , 1998, Atherosclerosis.

[4]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[5]  K. Donaghue,et al.  A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. , 1998, The Journal of clinical endocrinology and metabolism.

[6]  B L Miller,et al.  Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. , 1998, Stroke.

[7]  D. Sanghera,et al.  DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. , 1998, American journal of human genetics.

[8]  Griendling Kk,et al.  Oxidative stress and cardiovascular disease. , 1997 .

[9]  R. James,et al.  Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[10]  P. Durrington,et al.  Presence of paraoxonase in human interstitial fluid , 1997, FEBS letters.

[11]  P. Durrington,et al.  3.P.81 Immunolocalisation of paraoxonase with clusterin and apolipoprotein A1 in the human artery wall , 1997 .

[12]  D. Sanghera,et al.  Genetic polymorphism of paraoxonase and the risk of coronary heart disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[13]  R. Alexander,et al.  Oxidative stress and cardiovascular disease. , 1997, Circulation.

[14]  P. Froguel,et al.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. , 1997, The Journal of clinical investigation.

[15]  F. Fazekas,et al.  Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants. , 1996, Stroke.

[16]  B. La Du,et al.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. , 1996, Genomics.

[17]  R. Hegele,et al.  Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins , 1996, Current opinion in lipidology.

[18]  A. Marian,et al.  A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. , 1995, The Journal of clinical investigation.

[19]  A. Boulton,et al.  Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[20]  G. Charpentier,et al.  Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes , 1995, The Lancet.

[21]  J. Garcìa,et al.  The significance of cerebral white matter abnormalities 100 years after Binswanger's report. A review. , 1995, Stroke.

[22]  P. Jennings.  From hemobiology to vascular disease: a review of the potential of gliclazide to influence the pathogenesis of diabetic vascular disease. , 1994, Journal of diabetes and its complications.

[23]  F. Fazekas,et al.  Assessment of cerebrovascular risk profiles in healthy persons: definition of research goals and the Austrian Stroke Prevention Study (ASPS). , 1994, Neuroepidemiology.

[24]  A. Hofman,et al.  Cerebral white matter lesions, vascular risk factors, and cognitive function in a population‐based study , 1994, Neurology.

[25]  E P Steinberg,et al.  Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study. , 1994, Stroke.

[26]  C. Abbott,et al.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.

[27]  F. Fazekas,et al.  Pathologic correlates of incidental MRI white matter signal hyperintensities , 1993, Neurology.

[28]  A Hofman,et al.  Cerebral white matter lesions and atherosclerosis in the Rotterdam Study , 1993, The Lancet.

[29]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[30]  P. Durrington,et al.  Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.

[31]  D. Harman.  The aging process: major risk factor for disease and death. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  G Lantos,et al.  Brain white-matter changes in the elderly prone to falling. , 1989, Archives of neurology.

[33]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[34]  H Lechner,et al.  White matter signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. , 1988, Stroke.

[35]  T. H. Newton,et al.  Foci of MRI signal (pseudo lesions) anterior to the frontal horns: histologic correlations of a normal finding. , 1986, AJR. American journal of roentgenology.